Feasibility and efficacy of 8 week Glecaprevir/Pibrentasvir to treat incarcerated viraemic HCV patients: A case-control study.
Adult
Aminoisobutyric Acids
Antiviral Agents
/ therapeutic use
Benzimidazoles
Case-Control Studies
Cyclopropanes
Feasibility Studies
Genotype
Hepacivirus
/ genetics
Hepatitis C
/ drug therapy
Humans
Italy
Lactams, Macrocyclic
Leucine
/ analogs & derivatives
Middle Aged
Prisoners
Proline
/ analogs & derivatives
Pyrrolidines
Quinoxalines
Sulfonamides
Hepatitis C virus
case-control study
direct acting antivirals
incarcerated patients
prison settings
Journal
Liver international : official journal of the International Association for the Study of the Liver
ISSN: 1478-3231
Titre abrégé: Liver Int
Pays: United States
ID NLM: 101160857
Informations de publication
Date de publication:
02 2021
02 2021
Historique:
received:
27
04
2020
revised:
15
10
2020
accepted:
17
11
2020
pubmed:
24
11
2020
medline:
22
6
2021
entrez:
23
11
2020
Statut:
ppublish
Résumé
Inmates have higher HCV prevalence than general population, representing a fundamental step towards HCV eradication. Our aim was to compare 8-week glecaprevir/pibrentasvir treatment in a case-control study between incarcerated and free patients. Eleven Italian prisons and six outpatient clinics were involved. Patients were matched for sex, risk factors, METAVIR grade, HIV and HBV co-infections. About 131 incarcerated (Group A) and 131 free patients (Group B) were included. Mean age was 43.0 ± 9.6 years and 42.8 ± 9.9 in Group A and B, respectively (P = .74). SVR rates were 96.2% and 99.2% in Group A and Group B respectively (P = .21). Five drop-outs occurred in Group A, one in Group B. Incarceration, being PWIDs and OST were not associated with SVR reductions (CI 95%). In conclusion, imprisonment does not influence unplanned interruptions or SVR rates when receiving short-term therapies. Short schedules with pangenotypic regimens could be a good approach to hard-to-reach populations, such as incarcerated patients.
Substances chimiques
Aminoisobutyric Acids
0
Antiviral Agents
0
Benzimidazoles
0
Cyclopropanes
0
Lactams, Macrocyclic
0
Pyrrolidines
0
Quinoxalines
0
Sulfonamides
0
pibrentasvir
2WU922TK3L
Proline
9DLQ4CIU6V
Leucine
GMW67QNF9C
glecaprevir
K6BUU8J72P
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
271-275Informations de copyright
© 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol. 2017;2:161-176.
Weinbaum C, Lyerla R, Margolis HS. Centers for Disease Control and Prevention. Prevention and control of infections with hepatitis viruses in correctional settings. MMWR Recomm Rep. 2003;52(RR-1):1-36.
Larney S, Kopinski H, Beckwith CG, et al. Incidence and prevalence of hepatitis C in prisons and other closed settings: results of a systematic review and meta-analysis. Hepatology. 2013;58:1215-1224.
Sagnelli E, Starnini G, Sagnelli C, et al. Blood born viral infections, sexually transmitted diseases and latent tuberculosis in italian prisons: a preliminary report of a large multicenter study. Eur Rev Med Pharmacol Sci. 2012;16:2142-2146.
Polaris observatory data. http://polarisobservatory.org/polaris/graphs.htm. Accessed April 2, 2019
European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2018. J Hepatol. 2018;69:461-511.
Puoti M, Foster GR, Wang S, et al. High SVR12 with 8-week and 12-week glecaprevir/pibrentasvir therapy: An integrated analysis of HCV genotype 1-6 patients without cirrhosis. J Hepatol. 2018;69:293-300.
Pontali E, Fiore V, Ialungo AM, et al. Treatment with direct-acting antivirals in a multicenter cohort of HCV-infected inmates in Italy. Int J Drug Policy. 2018;59:50-53.
Overton K, Clegg J, Pekin F, et al. Outcomes of a nurse-led model of care for hepatitis C assessment and treatment with direct-acting antivirals in the custodial setting. Int J Drug Policy. 2019;72:123-128.
Persico M, Aglitti A, Milella M. Real-life glecaprevir/pibrentasvir in a large cohort of patients with hepatitis C virus infection: The MISTRAL study. Liver Int. 2019;39:1852-1859.
Vroling H, Oordt-Speets AM, Madeddu G, et al. A systematic review on models of care effectiveness and barriers to Hepatitis C treatment in prison settings in the EU/EEA. J Viral Hepat. 2018;25:1406-1422.
Papatheodoridis G, Thomas HC, Golna C, et al. Addressing barriers to the prevention, diagnosis and treatment of hepatitis B and C in the face of persisting fiscal constraints in Europe: report from a high level conference. J Viral Hepat. 2016;23(Suppl 1):1-12.
Bartlett SR, Fox P, Cabatingan H, et al. Demonstration of Near-Elimination of Hepatitis C Virus Among a Prison Population: The Lotus Glen Correctional Centre Hepatitis C Treatment Project. Clin Infect Dis. 2018;67:460-463.
Brandolini M, Novati S, De Silvestri A, et al. Prevalence and epidemiological correlates and treatment outcome of HCV infection in an Italian prison setting. BMC Public Health. 2013;2013(13):981.
Grebely J, Hajarizadeh B, Dore GJ. Direct-acting antiviral agents for HCV infection affecting people who inject drugs. Nat Rev Gastroenterol Hepatol. 2017;14:641-651.
Foster GR, Dore GJ, Wang S, et al. Glecaprevir/pibrentasvir in patients with chronic HCV and recent drug use: An integrated analysis of 7 phase III studies. Drug Alcohol Depend. 2019;194:487-494.
Girardin F, Hearmon N, Castro E, et al. Modelling the Impact and Cost-effectiveness of Extended Hepatitis C Virus Screening and Treatment with Direct-acting Antivirals in a Swiss Custodial Setting. Clin Infect Dis. 2019;69:1980-1986.
Assoumou SA, Tasillo A, Vellozzi C, et al. Cost-effectiveness and budgetary impact of HCV testing, treatment and linkage to care in U.S. prisons. Clin Infect Dis. 2019;ciz383.
Aspinall EJ, Mitchell W, Schofield J, et al. A matched comparison study of hepatitis C treatment outcomes in the prison and community setting, and an analysis of the impact of prison release or transfer during therapy. J Viral Hepatitis. 2016;23:1009-1016.
Mohamed Z, Al-Kurdi D, Nelson M, et al. Time matters: Point of care screening and streamlined linkage to care dramatically improves hepatitis C treatment uptake in prisoners in England. Int J Drug Policy. 2020;75:102608.